ReviewCNS neuroscience & therapeutics2008
Therapeutic potential of fluoxetine in neurological disorders.
Review in CNS neuroscience & therapeutics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 99 citations in OpenAlex.
- Trial
- Fluoxetine in progressive multiple sclerosis (FLUOX-PMS): study protocol for a randomized controlled trial.Trials · 2014Trial
- From Lab to Clinic: Success Stories of Repurposed Drugs in Treating Major Diseases.Advances in pharmacological and pharmaceutical sciences · 2025Review
- The Microbiota-Gut-Brain Axis in Depression: The Potential Pathophysiological Mechanisms and Microbiota Combined Antidepression Effect.Nutrients · 2022Review
- Mechanistic Insight on Autophagy Modulated Molecular Pathways in Cerebral Ischemic Injury: From Preclinical to Clinical Perspective.Neurochemical research · 2022Review
- Mechanisms Underlying the Interaction Between Chronic Neurological Disorders and Microbial MetabolitesFrontiers in microbiology · 2022Review
- Translating concepts of neural repair after stroke: Structural and functional targets for recovery.Restorative neurology and neuroscience · 2020Review
- Long-term Ameliorative Effects of the Antidepressant Fluoxetine Exposure on Cognitive Deficits in 3 × TgAD Mice.Molecular neurobiology · 2017Article
- Selective Serotonin Reuptake Inhibitors for Treating Neurocognitive and Neuropsychiatric Disorders Following Traumatic Brain Injury: An Evaluation of Current Evidence.Brain sciences · 2017Review
- Perspective: Neuroregenerative Nutrition.Advances in nutrition (Bethesda, Md.) · 2017Article
- Piperine potentiates the effects of trans-resveratrol on stress-induced depressive-like behavior: involvement of monoaminergic system and cAMP-dependent pathway.Metabolic brain disease · 2016Article
- 3,5,6,7,8,3',4'-Heptamethoxyflavone, a Citrus Flavonoid, Ameliorates Corticosterone-Induced Depression-like Behavior and Restores Brain-Derived Neurotrophic Factor Expression, Neurogenesis, and Neuroplasticity in the Hippocampus.Molecules (Basel, Switzerland) · 2016Article
- Effect of chronic fluoxetine treatment on audiogenic epilepsy, symptoms of anxiety and depression in rats of four lines.Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections · 2016Article
- Neuron-astrocyte interactions in neurodegenerative diseases: Role of neuroinflammation.Clinical & experimental neuroimmunology · 2015Article
- Antidepressant treatment response is modulated by genetic and environmental factors and their interactions.Annals of general psychiatry · 2014Review
- Molecular Advances Leading to Treatment Implications for Fragile X Premutation Carriers.Brain disorders & therapy · 2014Article
- Implications and limitations of cellular reprogramming for psychiatric drug development.Experimental & molecular medicine · 2013Review
- Neuroligin modulates the locomotory dopaminergic and serotonergic neuronal pathways of C. elegans.Neurogenetics · 2013Article
- Quetiapine fumarate for the treatment of multiple sclerosis: focus on myelin repair.CNS neuroscience & therapeutics · 2013Review
- Treatment trials in progressive MS--current challenges and future directions.Nature reviews. Neurology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The selective serotonin reuptake inhibitor (SSRI) fluoxetine, which is registered for a variety of psychiatric disorders, has been found to stimulate the cAMP-responsive element binding protein (CREB), increase the production of brain-derived neurotrophic factor (BNDF) and the neurotrophic peptide S100beta, enhance glycogenolysis in astrocytes, block voltage-gated calcium and sodium channels, and decrease the conductance of mitochondrial voltage-dependent anion channels (VDACs). These mechanisms of actions suggest that fluoxetine may also have potential for the treatment of a number of neurological disorders. We performed a Pubmed search to review what is known about possible therapeutic effects of fluoxetine in animal models and patients with neurological disorders. Beneficial effects of fluoxetine have been noted in animal models of stroke, multiple sclerosis, and epilepsy. Fluoxetine was reported to improve neurological manifestations in patients with Alzheimer's disease, stroke, Huntington's disease, multiple sclerosis, traumatic brain injury, and epilepsy. Clinical studies so far were small and often poorly designed. Results were inconclusive and contradictory. However, the available preclinical data justify further clinical trials to determine the therapeutic potential of fluoxetine in neurological disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.